Dysphagia Days as an Assessment of Clinical Treatment Outcome in Eosinophilic Esophagitis

Am J Gastroenterol. 2023 Apr 1;118(4):744-747. doi: 10.14309/ajg.0000000000002094. Epub 2022 Dec 20.


Introduction: The aim of this study was to evaluate Dysphagia Days as a measure of symptom improvement in patients with eosinophilic esophagitis from the HEROES study.

Methods: Dysphagia Days, defined as a yes answer to the following question: During any meal today, did food go down slowly or get stuck in your throat or chest? was assessed for cendakimab vs placebo.

Results: A statistically significant reduction in the mean number of Dysphagia Days experienced was observed with cendakimab 360 mg vs placebo at week 16 (-4.67 vs -1.83; P = 0.0115); an even greater improvement was observed in steroid-refractory patients vs placebo (-4.48 vs -0.04; P = 0.0079).

Discussion: Dysphagia Days represents a relevant clinical end point to capture dysphagia-related symptoms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Deglutition Disorders* / drug therapy
  • Deglutition Disorders* / etiology
  • Enteritis*
  • Eosinophilic Esophagitis* / complications
  • Eosinophilic Esophagitis* / diagnosis
  • Eosinophilic Esophagitis* / drug therapy
  • Esophagitis*
  • Humans
  • Treatment Outcome

Supplementary concepts

  • Eosinophilic enteropathy